{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-270358","form_type":"8-K","ticker":"NTLA","cik":"0001652130","company_name":"Intellia Therapeutics, Inc.","filed_at":"2026-06-15T12:52:21+00:00","discovered_at":"2026-06-15T12:55:00.540927+00:00","generated_at":"2026-06-15T12:55:08.712494+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Intellia reports positive Phase 3 HAELO results for lonvo-z; BLA rolling submission initiated","bullets":["89% reduction (p<0.0001) in monthly attacks requiring on-demand treatment vs placebo; 91% reduction in moderate/severe attacks.","62% of lonvo-z patients attack-free and therapy-free during weeks 5-28 vs 11% placebo (p<0.0001).","AE-QoL total score improved by -17.04 points vs placebo (p<0.0001); all TEAEs mild/moderate, no serious events in lonvo-z arm.","Rolling BLA submission started April 2026; company expects FDA approval and U.S. launch in first half 2027.","All patients in lonvo-z arm experienced attack-rate reductions; plasma kallikrein levels stable through Feb 2026 cutoff."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-270358","json":"https://secwatch.observer/filing/0001193125-26-270358.json","markdown":"https://secwatch.observer/filing/0001193125-26-270358.md","text":"https://secwatch.observer/filing/0001193125-26-270358.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1652130/000119312526270358/0001193125-26-270358-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1652130/000119312526270358/ntla-20260613.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T12:55:08.712494+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}